Anti-MDA5 Antibody-Positive Dermatomyositis in Emirati Patients: A Case Series Highlighting Clinical Variability
American Journal of Case Reports · 2026
DOI: 10.12659/ajcr.951064 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Case Reports, 2026. Verfasst von Deena Ahmed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Adult Rheumatology, Sheikh Sultan Bin Zayed Hospital, Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Dermatomyositis, Interferon-Induced Helicase, IFIH1, Autoantibodies, Lung Diseases, Interstitial. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND Melanoma differentiation-associated gene 5 (MDA5) is an intracellular sensor that detects double-stranded RNA viruses and triggers type I interferon pathways. Anti-MDA5 dermatomyositis (MDA5-DM) is an uncommon autoimmune subtype, often linked to rapidly progressive interstitial lung disease (RP-ILD) and sometimes presenting without obvious muscle weakness. It can appear in pulmonary, cutaneous-articular, or vascular forms, with RP-ILD carrying the worst prognosis. We describe 3 Emirati patients with MDA5-DM, each with a different clinical picture, organ involvement, and outcome. CASE REPORT Case 1: A 24-year-old man developed flu-like symptoms, rash, abnormal liver enzymes, and RP-ILD. His condition worsened despite high-dose steroids, cyclophosphamide, and plasma exchange; he required ECMO and died after 40 days. Case 2: A 62-year-old man with ILD presented with worsening dyspnea, weakness, and rash. He had high ferritin and lactate dehydrogenase levels, with positive anti-MDA5. He was treated with steroids, rituximab, nintedanib, and mycophenolate. High-resolution computerized tomography scans remained stable, but he required long-term oxygen after having pneumonia. Case 3: A 13-year-old boy had weight loss, stiffness, rash, and positive anti-MDA5. Magnetic resonance imaging confirmed myositis. He improved after steroids and intravenous immunoglobulin, with recovery of strength, weight gain, and normal function after prolonged treatment. CONCLUSIONS MDA5-DM is a rare and clinically diverse entity that can range from indolent skin-limited disease to life-threatening RP-ILD. This case series highlights the full clinical spectrum, from pediatric onset to fulminant adult disease. Multidisciplinary care, awareness of atypical presentations, and continued research into disease mechanisms and therapeutics are essential to improving survival in MDA5-DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Adult Rheumatology, Sheikh Sultan Bin Zayed Hospital, Sharjah, United Arab Emirates.
- Department of Pediatric & Adolescence Rheumatology, University Hospital of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom.
- Department of Adult Rheumatology, Sheikh Tahnoon Medical City, Al Ain, United Arab Emirates.
- Department of Adult Rheumatology, Sheikh Shakbout Medical City, Abu Dhabi, United Arab Emirates.
- Department of Rheumatology, Al Qassimi Hospital, Emirates Health Services, Sharjah, United Arab Emirates.
- Department of Hospital Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Zitieren
APA
Ahmed, D., Khawaja, K., Al Dhaheri, A., Alshamsi, A., Almheiri, A., Almarzooqi, A., Al Qassimi, S., Namas, R., & ElGhazali, G. (2026). Anti-MDA5 Antibody-Positive Dermatomyositis in Emirati Patients: A Case Series Highlighting Clinical Variability. American Journal of Case Reports. https://doi.org/10.12659/ajcr.951064
Vancouver
Ahmed D, Khawaja K, Al Dhaheri A, Alshamsi A, Almheiri A, Almarzooqi A, et al. Anti-MDA5 Antibody-Positive Dermatomyositis in Emirati Patients: A Case Series Highlighting Clinical Variability. American Journal of Case Reports. 2026. doi:10.12659/ajcr.951064
BibTeX
@article{Ahmed2026,
author = {Ahmed, Deena and Khawaja, Khulood and Al Dhaheri, Afra and Alshamsi, Abdulla and Almheiri, Amna and Almarzooqi, Ahlam and Al Qassimi, Sarah and Namas, Rajaie and ElGhazali, Gehad},
title = {Anti-MDA5 Antibody-Positive Dermatomyositis in Emirati Patients: A Case Series Highlighting Clinical Variability},
journal = {American Journal of Case Reports},
year = {2026},
doi = {10.12659/ajcr.951064}
}
EUVIMED